Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic spontaneous urticaria
Biotech
Evommune’s phase 2b flops, ending challenge to Novartis in hives
A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis for a skin disease market.
Nick Paul Taylor
Jun 29, 2026 10:00am
Inflammation biotech Evommune eyes IPO to fund dermatitis trials
Oct 10, 2025 6:35am
Jasper halves workforce after dud drug surprise, narrows R&D focus
Jul 9, 2025 9:07am
Jasper warns of restructuring after dud drug derails trials
Jul 7, 2025 9:23am
Third Harmonic’s song to end as biotech looks to liquidate
Apr 14, 2025 9:01am
Novartis hands over $55M to license preclinical hives prospect
Mar 3, 2025 5:05pm
